Retraction: Pioglitazone, a PPARγ Agonist, Suppresses CYP19 Transcription: Evidence for Involvement of 15-Hydroxyprostaglandin Dehydrogenase and BRCA1.
作者信息
Subbaramaiah Kotha, Howe Louise R, Zhou Xi Kathy, Yang Peiying, Hudis Clifford A, Kopelovich Levy, Dannenberg Andrew J
出版信息
Cancer Prev Res (Phila). 2022 Jun 2;15(6):411. doi: 10.1158/1940-6207.CAPR-22-0204.
Abstract
摘要
相似文献
1
Retraction: Pioglitazone, a PPARγ Agonist, Suppresses CYP19 Transcription: Evidence for Involvement of 15-Hydroxyprostaglandin Dehydrogenase and BRCA1.
Cancer Prev Res (Phila). 2022 Jun 2;15(6):411. doi: 10.1158/1940-6207.CAPR-22-0204.
2
PPARγ agonists target aromatase via both PGE2 and BRCA1.过氧化物酶体增殖物激活受体γ 激动剂通过前列腺素 E2 和乳腺癌易感基因 1 靶向芳香化酶。
Cancer Prev Res (Phila). 2012 Oct;5(10):1169-72. doi: 10.1158/1940-6207.CAPR-12-0365.
3
Further evidence for the involvement of the PPARγ system on alcohol intake and sensitivity in rodents.进一步证明了 PPARγ 系统在啮齿类动物的酒精摄入和敏感性中的作用。
Psychopharmacology (Berl). 2020 Oct;237(10):2983-2992. doi: 10.1007/s00213-020-05586-w. Epub 2020 Jul 16.
4
The PPARγ agonist pioglitazone prevents TGF-β induced renal fibrosis by repressing EGR-1 and STAT3.过氧化物酶体增殖物激活受体γ激动剂吡格列酮通过抑制 EGR-1 和 STAT3 预防 TGF-β诱导的肾纤维化。
BMC Nephrol. 2019 Jul 5;20(1):245. doi: 10.1186/s12882-019-1431-x.
5
Peroxisome proliferator-activated receptor-{gamma} suppresses CYP11B2 expression and aldosterone production.过氧化物酶体增殖物激活受体-γ 抑制 CYP11B2 的表达和醛固酮的产生。
J Mol Endocrinol. 2011 Jan 19;46(1):37-49. doi: 10.1677/JME-10-0088. Print 2011 Feb.
6
PPARγ agonist pioglitazone inhibits microglia inflammation by blocking p38 mitogen-activated protein kinase signaling pathways.过氧化物酶体增殖物激活受体γ激动剂吡格列酮通过阻断 p38 丝裂原活化蛋白激酶信号通路抑制小胶质细胞炎症。
Inflamm Res. 2010 Nov;59(11):921-9. doi: 10.1007/s00011-010-0203-7. Epub 2010 May 21.
7
The inhibition of the breast cancer by PPARγ agonist pioglitazone through JAK2/STAT3 pathway.吡格列酮通过 JAK2/STAT3 通路抑制乳腺癌。
Neoplasma. 2020 Jul;67(4):834-842. doi: 10.4149/neo_2020_190805N716. Epub 2020 May 6.
8
Pioglitazone, a PPARgamma ligand, suppresses NFkappaB activation through inhibition of IkappaB kinase activation in cerulein-treated AR42J cells.吡格列酮，一种过氧化物酶体增殖物激活受体γ（PPARγ）配体，通过抑制雨蛙肽处理的AR42J细胞中IκB激酶的激活来抑制核因子κB（NFκB）的激活。
Biomed Pharmacother. 2008 Sep;62(7):466-72. doi: 10.1016/j.biopha.2007.10.012. Epub 2007 Dec 17.
9
Neuroprotective and antioxidative effects of pioglitazone in brain tissue adjacent to the ischemic core are mediated by PI3K/Akt and Nrf2/ARE pathways.吡格列酮通过 PI3K/Akt 和 Nrf2/ARE 通路对缺血核心区脑组织发挥神经保护和抗氧化作用。
J Mol Med (Berl). 2021 Aug;99(8):1073-1083. doi: 10.1007/s00109-021-02065-3. Epub 2021 Apr 16.
10
Pioglitazone, a PPARγ agonist, provides comparable protection to angiotensin converting enzyme inhibitor ramipril against adriamycin nephropathy in rat.吡格列酮，一种过氧化物酶体增殖物激活受体γ（PPARγ）激动剂，在大鼠中对阿霉素肾病提供了与血管紧张素转换酶抑制剂雷米普利相当的保护作用。
Eur J Pharmacol. 2014 May 5;730:51-60. doi: 10.1016/j.ejphar.2014.02.023. Epub 2014 Feb 28.
本文引用的文献
1
Pioglitazone, a PPARγ agonist, suppresses CYP19 transcription: evidence for involvement of 15-hydroxyprostaglandin dehydrogenase and BRCA1.吡格列酮，一种过氧化物酶体增殖物激活受体 γ 激动剂，可抑制 CYP19 的转录：涉及 15-羟基前列腺素脱氢酶和 BRCA1 的证据。
Cancer Prev Res (Phila). 2012 Oct;5(10):1183-94. doi: 10.1158/1940-6207.CAPR-12-0201. Epub 2012 Jul 10.
Zotero 插件